Insulet Corp. (NASDAQ: PODD) is a Healthcare company (Medical - Devices) with a market capitalization of $10.1B. The Maz Rating grades it against the other companies in its sector.
Insulet Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $145.34, Insulet Corp. trades at 23.6x trailing earnings, 3.2x sales and 6.4x book value, with an EV/EBITDA of 15.2. Over the last twelve months it generated about $3.2B of revenue and $427M of net income. It runs a gross margin of 71.9%, an operating margin of 18.4% and a net margin of 13.4%. It shows return on equity of 29.5%, return on invested capital of 17.5% and a free cash flow yield of 2.6%. On the balance sheet: a debt-to-equity ratio of 0.61 and a current ratio of 2.51. Over the past 52 weeks the share price ranged from $126.40 to $354.88, with a beta of 1.06.
Insulet Corp. does not currently pay a dividend.
50 Wall Street analyst ratings cover the stock: 28 Buy, 20 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.